4D Molecular Therapeutics (FDMT) Income towards Parent Company (2020 - 2025)
Historic Income towards Parent Company for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to -$56.9 million.
- 4D Molecular Therapeutics' Income towards Parent Company fell 2968.16% to -$56.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$209.1 million, marking a year-over-year decrease of 4583.13%. This contributed to the annual value of -$160.8 million for FY2024, which is 5974.31% down from last year.
- As of Q3 2025, 4D Molecular Therapeutics' Income towards Parent Company stood at -$56.9 million, which was down 2968.16% from -$54.6 million recorded in Q2 2025.
- 4D Molecular Therapeutics' Income towards Parent Company's 5-year high stood at -$7.6 million during Q2 2021, with a 5-year trough of -$56.9 million in Q3 2025.
- Over the past 5 years, 4D Molecular Therapeutics' median Income towards Parent Company value was -$28.7 million (recorded in 2023), while the average stood at -$31.6 million.
- Per our database at Business Quant, 4D Molecular Therapeutics' Income towards Parent Company skyrocketed by 6070.82% in 2023 and then tumbled by 33416.52% in 2024.
- 4D Molecular Therapeutics' Income towards Parent Company (Quarter) stood at -$25.1 million in 2021, then decreased by 9.2% to -$27.4 million in 2022, then fell by 17.86% to -$32.3 million in 2023, then crashed by 53.85% to -$49.6 million in 2024, then dropped by 14.51% to -$56.9 million in 2025.
- Its Income towards Parent Company was -$56.9 million in Q3 2025, compared to -$54.6 million in Q2 2025 and -$48.0 million in Q1 2025.